ASTRIA THERAPEUTICS INC (ATXS) Forecast, Price Target & Analyst Ratings
NASDAQ:ATXS • US04635X1028
12.58 USD
+0.08 (+0.64%)
At close: Jan 22, 2026
12.58 USD
0 (0%)
After Hours: 1/22/2026, 8:23:15 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ASTRIA THERAPEUTICS INC (ATXS).
Forecast Snapshot
Consensus Price Target
$21.62
+ 71.89% Upside
Next Earnings Forecast
Release DateMar 9, 2026
PeriodQ4 / 2025
EPS Estimate-$0.49
Revenue Estimate8.16M
ChartMill Buy Consensus
71.43%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$21.62
Upside
+ 71.89%
From current price of $12.58 to mean target of $21.62, Based on 14 analyst forecasts
Low
$13.13
Median
$13.26
High
$36.75
Price Target Revisions
1 Month
0.00%
3 Months
-17.94%
Price Target Summary
14 analysts have analysed ATXS and the average price target is 21.62 USD. This implies a price increase of 71.89% is expected in the next year compared to the current price of 12.58.
The average price target has been revised downward by 17.94% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
71.43%
ATXS was analyzed by 14 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about ATXS.
In the previous month the buy percentage consensus was at a similar level.
ATXS was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-12 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2025-10-16 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-10-15 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2025-10-15 | Wedbush | Downgrade | Outperform -> Neutral |
| 2025-10-14 | Jefferies | Downgrade | Buy -> Hold |
| 2025-09-17 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-13 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-04-29 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-03 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-31 | JMP Securities | Initiate | Market Outperform |
| 2025-01-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | Oppenheimer | Maintains | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 9, 2026
PeriodQ4 / 2025
EPS Estimate-$0.49
Revenue Estimate8.16M
Revenue Q2QN/A
EPS Q2Q-144.97%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
166.67%
Revenue (3 Months)
166.67%
EPS (1 Month)
13.32%
EPS (3 Months)
13.05%
Next Earnings Summary
ATXS is expected to report earnings on 3/9/2026. The consensus EPS estimate for the next earnings is -0.49 USD and the consensus revenue estimate is 8.16M USD.
The next earnings revenue estimate has been revised upward by 166.67% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 500K | -100.00% | 8.74M | 3.57M -59.15% | 4.264M 19.44% | 60.85M 1,327.06% | 241.65M 297.12% | 448.51M 85.60% | 627.47M 39.90% | 792.02M 26.22% | 685.89M -13.40% | |||||||||
| EBITDA YoY % growth | -31.46M | -35.16M -11.76% | -26.79M 23.81% | N/A 2.02% | N/A -3.09% | -35.904M -32.68% | -197.982M -451.42% | -52.938M 73.26% | -71.298M -34.68% | -114.24M -60.23% | -162.282M -42.05% | -182.784M -12.63% | -200.226M -9.54% | -209.712M -4.74% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -31.66M | -35.56M -12.32% | -27.09M 23.82% | -27.475M 2.66% | -28.27M -2.73% | -38.148M -38.21% | -197.657M -420.78% | -54M 72.56% | -80.417M -26.79% | -115.558M -64.46% | -142.552M -27.78% | -158.677M -11.31% | -162.414M -2.36% | -140.319M 13.60% | -3.929M 97.20% | 110.39M 2,909.35% | 232.86M 110.94% | 346.65M 48.87% | 350.6M 1.14% | |
| Operating Margin | N/A | N/A | -5,418.00% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1,631.03% | -4,444.73% | -3,808.95% | -230.60% | -1.63% | 24.61% | 37.11% | 43.77% | 51.12% | |
| EPS YoY % growth | N/A | -133.80 42.05% | -76.80 42.60% | -30.15 46.09% | -14.78 65.94% | -11.51 13.62% | -39.19 -17.49% | -3.58 74.63% | -2.32 33.33% | -1.69 40.91% | -2.20 -53.66% | -2.27 -3.42% | -2.01 11.72% | -1.98 1.53% | -0.83 58.18% | -0.95 -14.81% | 1.13 218.82% | 2.29 103.17% | 3.41 48.78% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.49 -144.97% | -0.59 -1.25% | -0.60 -5.22% | -0.61 -11.55% | -0.63 -28.25% | -0.79 -34.26% | -0.65 -7.99% | -0.69 -11.89% | -0.72 -15.26% |
| Revenue Q2Q % growth | 8.16M | 1.02M | 1.02M | 1.02M 44.48% | 1.02M -87.50% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -46.92M -52.82% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -30.294M -2.38% | -36.887M 0.29% | -37.358M -4.29% | -37.867M -11.03% | -38.722M -27.82% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-11.95%
EPS Next 5 Year
7.30%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-20.11%
EBIT Next 5 Year
-16.07%
ASTRIA THERAPEUTICS INC / ATXS Forecast FAQ
What do analysts expect the price target to be for ASTRIA THERAPEUTICS INC (ATXS)?
14 analysts have analysed ATXS and the average price target is 21.62 USD. This implies a price increase of 71.89% is expected in the next year compared to the current price of 12.58.
What is the next earnings date for ATXS stock?
ASTRIA THERAPEUTICS INC (ATXS) will report earnings on 2026-03-09, after the market close.
What are the consensus estimates for ATXS stock next earnings?
The consensus EPS estimate for the next earnings of ASTRIA THERAPEUTICS INC (ATXS) is -0.49 USD and the consensus revenue estimate is 8.16M USD.
What is the consensus rating for ATXS stock?
The consensus rating for ASTRIA THERAPEUTICS INC (ATXS) is 71.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.